NEW YORK – Schott Minifab, a subsidiary of Schott focused on microfluidics for point-of-care and life sciences consumables, announced on Tuesday that it is acquiring Applied Microarrays.
Financial and other terms of the deal were not disclosed. It is expected to close in early October.
The acquisition will expand Schott Minifab's biosensor printing capabilities and "further strengthen Schott Minifab's ability to offer a single-source contract manufacturing solution," the company said in a statement.
Applied Microarrays, or AMI, will move from Tempe, Arizona, to a larger location in Phoenix, which will increase Australia-based Schott Minifab's manufacturing footprint in the US.
Greg Wolters, head of Schott Minifab, said in a statement that AMI will help the company enhance its capabilities in surface modification, functionalization, and deposition for its glass and polymer products. Schott acquired Minifab, a provider of customized polymer microfluidics, in 2019.
The companies have previously worked together to develop biotech substrates for diagnostics applications. AMI served as parent company Schott's North American distributor starting in 2013.
AMI designs, optimizes, and manufactures DNA and protein biosensors and other microarrays on glass, plastic, and semiconductors. It acquired GE Healthcare's microarray business in 2007.